Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
NCT04217057Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2020
- Primary completion
- Feb 2023
- Modality
- Positron Emission Tomography Imaging
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Cu-DOTA-ECL1i in head and neck cancer (HNC), sponsored by Washington University School of Medicine. Primary endpoints: Diagnostic Quality of 64Cu-DOTA-ECL1i-PET/CT Images as Measured by Assessment of Overall Image Quality at Day 1, Diagnostic Quality of 64Cu-DOTA-ECL1i-PET/CT Images as Measured by Presence or Absence of Abnormal 64Cu-DOT-ECL1i Uptake at Day 1 and 1 more. Started Feb 2020; status: terminated.
02
Drugs
Cu-DOTA-ECL1i
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT04217057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04217057.